Edition:
United States

Heat Biologics Inc (HTBX.OQ)

HTBX.OQ on NASDAQ Stock Exchange Capital Market

0.86USD
28 Mar 2017
Change (% chg)

-- (--)
Prev Close
$0.86
Open
--
Day's High
--
Day's Low
--
Volume
--
Avg. Vol
328,796
52-wk High
$3.35
52-wk Low
$0.40

HTBX.OQ

Chart for HTBX.OQ

About

Heat Biologics, Inc. is a development-stage company focused on developing allogeneic, off-the-shelf cellular therapeutic vaccines to combat a range of cancers. The Company is an immuno-oncology company, which focuses on T cell-stimulating platform technologies, such as Immune Pan-Antigen Cytotoxic Therapy (ImPACT) and Combinatio... (more)

Overall

Beta: 0.79
Market Cap(Mil.): $28.81
Shares Outstanding(Mil.): 33.50
Dividend: --
Yield (%): --

Financials

  HTBX.OQ Industry Sector
P/E (TTM): -- 49.04 30.15
EPS (TTM): -1.52 -- --
ROI: -152.92 -2.17 13.05
ROE: -182.76 5.20 14.20

BRIEF-Heat Biologics prices offering of 5,000,000 shares of common stock

* Says public offering of 5.00 million common shares priced at $0.80per share

Mar 23 2017

BRIEF-Heat Biologics management estimates cash of about $7.8 mln at Dec 31 2016

* Heat Biologics Inc- management estimates cash of approximately $7.8 million at December 31, 2016.

Mar 23 2017

BRIEF-Heat Biologics announces proposed public offering of common stock

* Heat Biologics announces proposed public offering of common stock

Mar 22 2017

BRIEF-Heat Biologics reports positive results from mid-stage lung cancer trial

* Heat Biologics reports positive interim phase 2 lung cancer results in patients treated with hs-110 in combination with a checkpoint inhibitor

Mar 21 2017

BRIEF-Florida Dept Of Health awards Heat Biologics 3-year grant to develop zika vaccine

* Florida Department Of Health awards three-year grant to develop GP96-based zika vaccine

Mar 16 2017

BRIEF-Heat Biologics Meets Efficacy Endpoint in Phase 1B Lung Cancer Trial

* Heat biologics meets efficacy endpoint in its phase 1b lung cancer trial to progress to phase 2

Mar 13 2017

BRIEF-Heat Biologics to acquire Pelican Therapeutics

* Heat Biologics Inc - acquisition brings $15.2 million cprit grant to fund 70-patient Phase I trial

Mar 08 2017

BRIEF-Heat Biologics presents immune data on bladder cancer drug

* Researchers reported that hs-410, in combination with bcg, continues to be generally well-tolerated

Feb 17 2017

BRIEF-Heat Biologics filed prospectus supplement to which it may sell shares, par value $0.0002 per share on Feb. 3, 2017

* Heat Biologics - on February 3, 2017 filed prospectus supplement to which it may sell shares, par value $0.0002 per share, having an aggregate offering price of $17.5 million Source text (http://bit.ly/2koDBMw) Further company coverage:

Feb 03 2017

BRIEF-Heat Biologics reports Q3 loss per share $0.08

* Says it looks forward to reporting top-line data in both its bladder and lung cancer trials within next few weeks

Nov 10 2016

More From Around the Web

Earnings vs. Estimates